Month: October 2022

Insurance Types Impact Quality Of Care For Patients With Gynecologic Cancers

Targeted Oncology (10/14, Sava) reported, “Whether a patient with gynecologic cancer has insurance or is underinsured, there are major barriers which currently exist in accessing and affording quality care for the treatment of their cancer.” Such “disparities are a major problem as they contribute to one-third of women with gynecologic cancer never visiting a gynecologic oncologist, even […]

Read More

First-Line Maintenance Rucaparib Yields Higher PFS Compared With Newly Diagnosed Ovarian Cancer

Cancer Network  (9/30, Conroy) reported, “First-line maintenance rucaparib (Rubraca) yielded higher progression-free survival (PFS) compared with placebo among patients with newly diagnosed ovarian cancer regardless of cytoreductive surgery outcome and was favored across all subgroups, according to the results of the phase 3 ATHENA-MONO study.” These results were presented at the International Gynecologic Cancer Society 2022 […]

Read More